<DOC>
	<DOCNO>NCT00167180</DOCNO>
	<brief_summary>The purpose study test hypothesis pre-infusion preparative regimen cyclophosphamide fludarabine improve effectiveness DLI patient blood cancer .</brief_summary>
	<brief_title>Post Transplant Donor Lymphocyte Infusion</brief_title>
	<detailed_description>When cancer relapse donor bone marrow transplantation , regular dose chemotherapy offer little hope prolong survival . However , evidence lymphocyte attack cancer cell . There considerable evidence immune attack cancer cell associate graft-versus-host disease . Although graft-versus-host disease cause problem , immune reaction may , part , way bone marrow transplantation cure cancer . In study hope infusion immune cell subject 's bone marrow donor plus chemotherapy regimen cyclophosphamide fludarabine activate subject 's immune system attack cancer .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Patients ( age &gt; = 1 year ) diagnosis relapse relate unrelated allogeneic stem cell transplantation hematological malignancy . For CML , relapse define cytogenetic evidence Philadelphia chromosome persistence BCR/ABL rearrangements molecular test least two measurement 6 month interval . If cytogenetics normal PCR evidence BCR/ABL fusion , patient eligible evidence quantitative increase CML measure either quantitative PCR fluorescent situ hybridization ( FISH ) . For nonCML , relapse define base disease specific morphologic criterion bone marrow biopsy aspirate recurrence disease specific cytogenetics . For disease specific definition relapse , see appendix 3 . Relapse determine morphologically less 5 percent blast definitive relapse determine . Equivocal result relapse result repeat test appropriate time interval ( suggested 1 month ) determine eligibility . Posttransplant lymphoproliferative disease ( often refer EBVassociated lymphoma ) NOT eligible protocol . For Chronic Phase CML patient must fail ( response 3 month incomplete response 6 month ) refuse treatment Gleevec prior DLI , CML patient first DLI relapse occur DLI , DLI chemotherapy per protocol offer Patients must within one year identification relapse beyond time period , must least 10 % donor DNA RFLP cytogenetics . Same allogeneic donor ( sibling URD ) use transplantation available lymphocyte donation . No severe organ damage ( laboratory clinical assessment ) measure : blood creatinine ≤ 2.0 mg/dL liver function test &lt; 5 x normal leave ventricular ejection fraction &gt; 40 % ( test require symptomatic prior know impairment ) . pulmonary function &gt; 50 % ( test require symptomatic prior know impairment ) . Oxygen saturation ( &gt; 92 % ) use child PFT 's obtain . chest xray without evidence active infection Off prednisone immunosuppressive agent ( give reason ) least 3 day prior DLI infusion . Performance status ≥ 60 % Women must pregnant lactating . The agent use study may teratogenic fetus information excretion agent breast milk All females childbearing potential must blood test urine study within 2 week prior registration rule pregnancy Women childbearing potential sexually active male strongly advise use accept effective method contraception Patient must give write informed consent indicate understanding nature treatment potential risk Concurrent sign acute chronic graftversushost disease require ongoing treatment time relapse ineligible . Patients treat GVHD prednisone , cyclosporine , Imuran immunosuppressive medication eligible medication discontinue least 2 week without flare GVHD . Active CNS leukemia Active fungal infection pulmonary infiltrates ( stable prior treated disease allowable ) HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>donor lymphocyte infusion</keyword>
	<keyword>BMT</keyword>
	<keyword>bone marrow transplant</keyword>
</DOC>